85 related articles for article (PubMed ID: 26906101)
1. Overall condition improvement in a rat model of nephrotic syndrome treated with CellCept nanoliposomes.
Teng J; Zang L; Li L; Qiu X; Liu Y; Sun F
Artif Cells Nanomed Biotechnol; 2017 Feb; 45(1):128-134. PubMed ID: 26906101
[TBL] [Abstract][Full Text] [Related]
2. Different effect of cyclosporine A and mycophenolate mofetil on passive Heymann nephritis in the rat.
Blume C; Heise G; Hess A; Waldner C; Grabensee B; Schroer K; Heering P
Nephron Exp Nephrol; 2005; 100(2):e104-12. PubMed ID: 15855806
[TBL] [Abstract][Full Text] [Related]
3. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
Kwinta-Rybicka J; Wilkosz K; Wierzchowska-Słowiacze EK; Ogarek I; Moczulska A; Stec Z; Pełkowska A; Sancewicz-Pach K; Pietrzyk JA
Przegl Lek; 2006; 63 Suppl 3():44-8. PubMed ID: 16898486
[TBL] [Abstract][Full Text] [Related]
4. [Mycophenolate mofetil in the treatment of primary nephrotic syndrome].
Zhao M; Chen X; Chen Y; Liu Z; Liu Y; Lu F; Zhang Y; Wang H
Zhonghua Yi Xue Za Zhi; 2001 May; 81(9):528-31. PubMed ID: 11809115
[TBL] [Abstract][Full Text] [Related]
5. Effect of Poria cocos hydroethanolic extract on treating adriamycin-induced rat model of nephrotic syndrome.
Zan JF; Shen CJ; Zhang LP; Liu YW
Chin J Integr Med; 2017 Dec; 23(12):916-922. PubMed ID: 28035538
[TBL] [Abstract][Full Text] [Related]
6. Tripterygium glycoside fraction n2 ameliorates adriamycin-induced nephrotic syndrome in rats by suppressing apoptosis.
Wang XW; Tian RM; Yang YQ; Wang K; Li EN; Han XD; Bao K; Mao W; Xu HT; Liu B; Xu P
J Ethnopharmacol; 2020 Jul; 257():112789. PubMed ID: 32234597
[TBL] [Abstract][Full Text] [Related]
7. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
Nakhoul F; Ramadan R; Khankin E; Yaccob A; Kositch Z; Lewin M; Assady S; Abassi Z
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F880-90. PubMed ID: 15942045
[TBL] [Abstract][Full Text] [Related]
8. [A prospective multicenter clinical control trial on treatment of refractory nephrotic syndrome with mycophenolate mofetil in children].
Yi ZW; Wu XC; Xu H; Zhou LJ; Wu YB; Feng SP; Zhou JH; Yang Q; Zhu GH; Liu AM; Wei MJ; Yu L; Zeng ZF
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Oct; 10(5):575-8. PubMed ID: 18947472
[TBL] [Abstract][Full Text] [Related]
9. [Experimental study in renal protective effect of tranilast on rats with adriamycin nephropathy].
Tao Y; Wu X; Li DD; Liu QF; Bo H; Wang XR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jan; 39(1):76-9. PubMed ID: 18390206
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of glycyrrhizin on nephrotic syndrome induced by adriamycin in rats.
Bi X; Zhu G; Han Z; Ye Y; Liang Y; Zhang L; Hao Z; Zeng G; He H; Zhong W
Clin Invest Med; 2009 Jun; 32(3):E229-38. PubMed ID: 19480741
[TBL] [Abstract][Full Text] [Related]
11. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study.
Li X; Tian J; Wu J; He Q; Li H; Han F; Li Q; Chen Y; Ni Q; Chen J
Clin Ther; 2009 Apr; 31(4):741-50. PubMed ID: 19446147
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil treatment in primary glomerular disease: one-year follow-up in steroid dependent and resistant nephrotic syndrome.
Tasanarong A; Thitiarchakul S
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S218-27. PubMed ID: 17044475
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats.
Romero F; Rodríguez-Iturbe B; Parra G; González L; Herrera-Acosta J; Tapia E
Kidney Int; 1999 Mar; 55(3):945-55. PubMed ID: 10027931
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center.
Fujinaga S; Ohtomo Y; Hirano D; Nishizaki N; Someya T; Ohtsuka Y; Kaneko K; Shimizu T
Clin Nephrol; 2009 Oct; 72(4):268-73. PubMed ID: 19825332
[TBL] [Abstract][Full Text] [Related]
15. [Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
Chen B; Zhang Y; Liu G; Guan GJ; Hou XH; Li XG; Liu JL
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):540-5. PubMed ID: 18649770
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity.
Yang CW; Ahn HJ; Kim WY; Li C; Kim HW; Choi BS; Cha JH; Kim YS; Kim J; Bang BK
Kidney Int; 2002 Jul; 62(1):20-30. PubMed ID: 12081560
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome.
Wang J; Mao J; Chen J; Fu H; Shen H; Zhu X; Liu A; Shu Q; Du L
Nephrology (Carlton); 2016 Jan; 21(1):21-7. PubMed ID: 26697959
[TBL] [Abstract][Full Text] [Related]
18. Vascular dysfunction in adriamycin nephrosis: different effects of adriamycin exposure and nephrosis.
Ulu N; Buikema H; van Gilst WH; Navis G
Nephrol Dial Transplant; 2008 Jun; 23(6):1854-60. PubMed ID: 18218687
[TBL] [Abstract][Full Text] [Related]
19. Effect of the lipoprotein lipase activator NO-1886 on adriamycin-induced nephrotic syndrome in rats.
Nakayama K; Hara T; Kusunoki M; Tsutsumi K; Minami A; Okada K; Sakamoto S; Ohnaka M; Miyata T; Nakamura T; Aoki T; Fukatsu A; Nakaya Y; Kakumu S
Metabolism; 2000 May; 49(5):588-93. PubMed ID: 10831167
[TBL] [Abstract][Full Text] [Related]
20. Assessment of mycophenolate mofetil for treatment of frequently relapsing nephrotic syndrome in children.
Yi ZW; Dang XQ; He QN; Wu XC; Cao Y; Huang DL; He XJ; Mo SH
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Dec; 32(6):938-40. PubMed ID: 18182707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
